The risk of AD and other types of ADRD was significantly lower in patients receiving a combination of angiotensin-II stimulating and inhibiting drugs, and significantly higher in those receiving other categories of antihypertensive drugs regardless of high or low adherence and in those with hypertension without receiving antihypertensive medications. This evidence concerns the gene AGT and Alzheimer disease.